title: Treatment of acute promyelocytic leukemia with arsenic trioxide without ATRA and/or chemotherapy.
abstract: BACKGROUND
  Arsenic trioxide is effective and approved for treatment of relapsed or refractory acute promyelocytic leukemia (APL) cases resistant to all-trans retinoic acid (ATRA), but its effect on new cases of APL is not clear.
  
  
  METHODS
  We studied 111 patients with APL. Arsenic trioxide was infused at 0.15 mg/kg daily dose, until complete remission was achieved. Then, after 28 days of rest, arsenic trioxide was infused daily for 28 days as consolidation therapy. We studied minimal residual disease (MRD) by semi-sensitive reverse transcription polymerase chain reaction (RT-PCR) on peripheral blood samples.
  
  
  RESULTS
  Complete remission was observed in 95 patients (85.6%). With the median (range) follow-up period of 16.5 (1-57) months, 1- and 2-year disease-free survival was 88.3% and 63.7%, respectively; 24 patients relapsed, 19 of whom achieved a second complete remission, again by arsenic trioxide. Third and fourth remissions were seen in some relapsed patients, again by arsenic trioxide. For patients in complete remission, 1- and 3-year survival was 95.5% and 87.6%, respectively. MRD was positive in four (8.3%) out of 48 cases during 1 year after remission induction; three of them relapsed clinically.
  
  
  CONCLUSIONS
  Arsenic trioxide is effective as first-line treatment for APL. Results of arsenic trioxide combination therapy with chemotherapy/ATRA requires further study.
authors.affiliation: Haematology, Oncology and BMT Research Centre, Tehran University of Medical Sciences, Tehran, Iran.
authors.forename: A
authors.initials: A
authors.lastname: Ghavamzadeh
authors.forename: K
authors.initials: K
authors.lastname: Alimoghaddam
authors.forename: S H
authors.initials: SH
authors.lastname: Ghaffari
authors.forename: S
authors.initials: S
authors.lastname: Rostami
authors.forename: M
authors.initials: M
authors.lastname: Jahani
authors.forename: R
authors.initials: R
authors.lastname: Hosseini
authors.forename: A
authors.initials: A
authors.lastname: Mossavi
authors.forename: E
authors.initials: E
authors.lastname: Baybordi
authors.forename: A
authors.initials: A
authors.lastname: Khodabadeh
authors.forename: M
authors.initials: M
authors.lastname: Iravani
authors.forename: B
authors.initials: B
authors.lastname: Bahar
authors.forename: Y
authors.initials: Y
authors.lastname: Mortazavi
authors.forename: M
authors.initials: M
authors.lastname: Totonchi
authors.forename: N
authors.initials: N
authors.lastname: Aghdami
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000077237:Arsenic Trioxide; D001152:Arsenicals / Q000627:therapeutic use*; D002648:Child; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D015473:Leukemia, Promyelocytic, Acute / Q000188:drug therapy*; D007964:Leukocytosis; D008297:Male; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000235:genetics / Q000378:metabolism; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy; D018365:Neoplasm, Residual / Q000188:drug therapy; D015514:Oncogene Proteins, Fusion / Q000235:genetics / Q000378:metabolism; D010087:Oxides / Q000627:therapeutic use*; D011379:Prognosis; D012074:Remission Induction; D020133:Reverse Transcriptase Polymerase Chain Reaction; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D001152:Arsenicals; D009363:Neoplasm Proteins; D015514:Oncogene Proteins, Fusion; D010087:Oxides; C093476:promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein; D000077237:Arsenic Trioxide